We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

28 hedge funds and large institutions have $25M invested in Eagle Pharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more capital invested

Capital invested by funds: $24.4M → $25M (+$561K)

0% more funds holding

Funds holding: 28 → 28 (0)

0% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 12

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

Holders
28
Holders Change
–
Holders Change %
0%
% of All Funds
0.8%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
5
Reduced
6
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PWAM
Park West Asset Management
California
+$2.48M
2
Northern Trust
Northern Trust
Illinois
+$354K
3
PP
Paloma Partners
Connecticut
+$164K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$140K
5
Bank of America
Bank of America
North Carolina
+$138K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$2.27M
2
BFA
BlackRock Fund Advisors
California
-$1M
3
Jennison Associates
Jennison Associates
New York
-$897K
4
BIT
BlackRock Institutional Trust
California
-$364K
5
State Street
State Street
Massachusetts
-$271K
Name Holding Trade Value Shares
Change 		Change in
Stake
BNP Paribas Financial Markets
26
BNP Paribas Financial Markets
France
$5.06K +$4.03K +353 New
Royal Bank of Canada
27
Royal Bank of Canada
Ontario, Canada
$4K – – –
Bank of Montreal
28
Bank of Montreal
Ontario, Canada
$1K +$912 +80 New
JP Morgan Chase
29
JP Morgan Chase
New York
– -$2.27M -177,650 Closed
BFA
30
BlackRock Fund Advisors
California
– -$1M -78,665 Closed
BIT
31
BlackRock Institutional Trust
California
– -$364K -28,510 Closed
SCA
32
SAC Capital Advisors
Connecticut
– -$348K -27,288 Closed
State Street
33
State Street
Massachusetts
– -$271K -21,290 Closed
Millennium Management
34
Millennium Management
New York
– -$164K -12,900 Closed
NFA
35
Nationwide Fund Advisors
Ohio
– -$138K -10,834 Closed
FAAS
36
First Allied Advisory Services
California
– -$134K -10,600 Closed
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
– -$78K -6,100 Closed
TA
38
Teachers Advisors
New York
– -$43K -3,400 Closed
BRWM
39
B. Riley Wealth Management
Tennessee
– -$13K -1,000 Closed
TRCT
40
Tower Research Capital (TRC)
New York
– -$8K -610 Closed
1
2

EGRX Hedge Fund Activity: Q2 2014 in Review

28 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q2 2014, worth a combined $25M — up 2.3% from $24.4M a quarter earlier.

Fund positioning in EGRX was balanced in Q2 2014: 12 funds opened new positions, 12 closed out, 5 added to existing stakes and 6 trimmed.

The largest buyer was Park West Asset Management, adding an estimated $2.48M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $2.27M sold.

  • 28 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q2 2014, unchanged from Q1 2014.
  • Funds reported $25M of Eagle Pharmaceuticals, Inc. stock for Q2 2014, up 2.3% quarter-over-quarter.
  • 12 funds opened new Eagle Pharmaceuticals, Inc. positions in Q2 2014 and 12 closed out, a net change of 0 holders.
  • The largest Eagle Pharmaceuticals, Inc. buyer in Q2 2014 was Park West Asset Management, an estimated $2.48M added.
  • The largest Eagle Pharmaceuticals, Inc. seller in Q2 2014 was JP Morgan Chase, an estimated $2.27M sold.

Based on aggregated 13F filings for Q2 2014.